Autophagy

2022 Hidradenitis Suppurativa Pipeline Insight Report - Featuring Janssen Biotech, AbbVie and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, July 18, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Abscess, HS, Hair follicle, HARP, Apocrine, III, Acquisition, Prognosis, Disease, Patient, Route, Bacteria, Smoking, Therapy, Inflammation, Technology, Groin, Myocardial rupture, Cellular senescence, C5a, Autophagy, Lymphocyte, Mesothelioma, Company, NDA, ROA, Dermis, Diagnosis, Neutrophil, Route of administration, Obesity, Administration, GPP, Medical device, Pharmaceutical industry, Hidradenitis, Hidradenitis suppurativa

This report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Hidradenitis Suppurativa pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Hidradenitis Suppurativa pipeline landscape.
  • A detailed picture of the Hidradenitis Suppurativa pipeline landscape is provided which includes the disease overview and Hidradenitis Suppurativa treatment guidelines.
  • The assessment part of the report embraces, in depth Hidradenitis Suppurativa commercial assessment and clinical assessment of the pipeline products under development.
  • Hidradenitis Suppurativa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments

Retrieved on: 
Monday, June 27, 2022
Trident, FDA, Necrosis, Patient, Ferroptosis, CEO, Biotechnology, Coronavirus, Nature, Clinical, Iron, Tissue, Trial of the century, GLOBE, Â, 3D, Hillstream loach, Biomarker, COVID-19, Cancer, Failure, U.S. Securities and Exchange Commission, Forward-looking statement, Apollo Hospitals, AACR, Lipid peroxidation, TME, Autophagy, Neoplasm, Bristol Myers Squibb, Private Securities Litigation Reform Act, Toxicity, Nivolumab, 2D, Nasdaq, B cell, Fibroblast, Artificial intelligence, Skin, Risk, ICIS, IMCD, Tumor microenvironment, Immunotherapy, Genotype, Monoclonal antibody, Safety, Security (finance), Apoptosis, Cell death, Pharmaceutical industry, Vaccine, Medical imaging, Sapiens

The study concluded that inducing the Ferroptotic pathway in combination with checkpoint blockade is a potential synergistic therapeutic approach.

Key Points: 
  • The study concluded that inducing the Ferroptotic pathway in combination with checkpoint blockade is a potential synergistic therapeutic approach.
  • We are initiating studies, in collaboration with Sapien Biosciences, to determine the synergy between HSB-1216, our ferroptosis inducer and nivolumab, an anti-PD1 antibody, said Randy Milby, Hillstreams Chief Executive Officer.
  • We are excited to extend our collaboration with Hillstream Biopharma to evaluate potential synergy between their HSB-1216 molecule and ICIs using our expertise in establishing patient tissue-derived cell models in oncology, immunology and Immune-oncology,said Dr. Jugnu Jain, CEO, Sapien Biosciences.
  • Previously, Sapien demonstrated potent anti-cancer activity of HSB-1216 in primary triple negative breast cancer cells which were presented at AACR 2020.

Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

Retrieved on: 
Thursday, June 23, 2022
Pathology, Security (finance), Vance DeGeneres, Therapy, Leonard M. Miller School of Medicine, Safety, CSF, Private Securities Litigation Reform Act, Neuron, Cognition, Lewy, Biology, Ageing, SHIMMER, Brain, Lewy body, U.S. Securities and Exchange Commission, Lewy Body Dementia Association, Hallucination, Degenerative disease, National Institute on Aging, Disease, Cerebrospinal fluid, DLB, Central nervous system, University, National, National Institute, Delusion, Autophagy, Biomarker, Sleep, Nasdaq, Head, Patient, Retina, MPH, Dementia, Diagnosis, LBDA, Risk, GLOBE, Pharmaceutical industry, Medicine, MD

NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) today announced that the first patient has been dosed in its double-blind, placebo-controlled, randomized Phase 2 SHIMMER clinical trial of CT1812 in patients with dementia with Lewy bodies (DLB). CT1812 is an experimental, orally delivered small molecule therapeutic intended to address the underlying biology of DLB.

Key Points: 
  • NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (Nasdaq: CGTX) today announced that the first patient has been dosed in its double-blind, placebo-controlled, randomized Phase 2 SHIMMER clinical trial of CT1812 in patients with dementia with Lewy bodies (DLB) .
  • Further evidence suggests that these processes are regulated by the sigma-2 (-2) receptor, which is the biological target of CT1812.
  • Initiation of patient treatment in this interventional study is an important milestone for Cognition Therapeutics and for the DLB community.
  • We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimers disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD).

Startup Vitalunga creates novel oral drug to enable disease-free aging; pre-clinical studies expected to begin in near future

Retrieved on: 
Monday, June 13, 2022
UN, Research, Cell, Johnson & Johnson, Autophagy, ICL, CEO, Disease, Solution, Intel, Manuscript, Growth, Quality of life, Novartis, Population, Industry, Eleazar Sukenik, Merck, Mitophagy, Tissue, Hebrew University of Jerusalem, Ageing, Boston Scientific, Pharmaceutical industry, Medicine, Yissum Research Development Company of the Hebrew University

JERUSALEM, June 13, 2022 /PRNewswire/ -- Vitalunga, the biotech startup based on the research led by Professor Einav Gross and Professor Shmuel Ben-Sasson of The Hebrew University's Faculty of Medicine, has developed a novel oral drug that aims to treat and prevent aging-related diseases such as Alzheimer's and Parkinson's. While many successes have been made to extend lifespan in aging adults, disease-free aging has remained a challenge. The novel drug-candidate has the potential to remarkably improve the quality of life of aging adults, Yissum, the technology transfer company of the Hebrew University announced today. Vitalunga is currently raising funds in order to begin pre-clinical studies.

Key Points: 
  • While many successes have been made to extend lifespan in aging adults, disease-free aging has remained a challenge.
  • The novel drug-candidate has the potential to remarkably improve the quality of life of aging adults, Yissum, the technology transfer company of the Hebrew University announced today.
  • Vitalunga is currently raising funds in order to begin pre-clinical studies.
  • The discovery of these compounds led Vitalunga to the development of further more advanced novel agents, targeting prevention of aging-associated deterioration.

Juvenescence joins Banco Português de Fomento and 200M Fund in co-investment in Chrysea Laboratories

Retrieved on: 
Friday, June 10, 2022
BPF, CEO, Fomento, Solution, Metabolism, Autophagy, History, Synthetic biology, Fund, Ageing, Venture round, Fine chemical, Dietary supplement, Pharmaceutical industry, Clathrina chrysea

RAMSEY, ISLE OF MAN, June 10, 2022 /PRNewswire/ -- Juvenescence Limited ("Juvenescence"), through its JuvLife Division, joins the 200M Fund portfolio, managed by Banco Portugus de Fomento, in the Venture Round investment in Chrysea Labs ("Chrysea"), a synthetic biology company developing high-value and difficult to source natural products, using proprietary synthetic biology platforms.

Key Points: 
  • RAMSEY, ISLE OF MAN, June 10, 2022 /PRNewswire/ -- Juvenescence Limited ("Juvenescence"), through its JuvLife Division, joins the 200M Fund portfolio, managed by Banco Portugus de Fomento, in the Venture Round investment in Chrysea Labs ("Chrysea"), a synthetic biology company developing high-value and difficult to source natural products, using proprietary synthetic biology platforms.
  • Juvenescence and Chrysea will collaborate to develop and commercialise one of Chrysea's products.
  • Banco Portugus de Fomento invested 3.7 million euros (3,721,387.04) in Chrysea, through the 200M Co-investment Fund.
  • For Beatriz Freitas, CEO of Banco Portugus de Fomento, the managing entity of the 200M Fund, "it is with great enthusiasm that the 200M Fund supports Chrysea's project of developing precision nutritional products supported by rigorous clinical research, aimed at supporting successful ageing and a healthy lifespan.

Casma Therapeutics to Present at UBS 2022 Global Healthcare Conference

Retrieved on: 
Tuesday, May 17, 2022
UBS, Inflammation, Disease, Organelle, Lists of diseases, Patient, Arrest, Protein, Therapy, Autophagy, Conference, Neurodegeneration, Drug discovery, GLOBE, Pharmaceutical industry

CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Casma Therapeutics , Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., Chief Executive Officer, will present at the UBS 2022 Global Healthcare Conference on Tuesday, May 24, 2022 at 11:30 a.m.

Key Points: 
  • CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Casma Therapeutics , Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., Chief Executive Officer, will present at the UBS 2022 Global Healthcare Conference on Tuesday, May 24, 2022 at 11:30 a.m.
  • Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy pathway to open new target areas for drug discovery and development that will profoundly impact the lives of patients.
  • The autophagy machinery targets larger and more complex disease targets such as organelles, protein aggregates and large signaling complexes and directs them to the lysosome for elimination.
  • By selectively degrading disease targets by autophagy, Casma expects to be able to arrest or reverse the progression of disease in multiple oncology, inflammation, neurodegeneration and metabolic disorders.

AriBio Co., Ltd. Announces the Successful Completion of Their End of Phase 2 Meeting With the USFDA

Retrieved on: 
Wednesday, May 4, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Mental Health, Clinical Trials, Drug development, Tau, Thought, Division, University, Statistics, Biostatistics, Time, EST, Neurodegeneration, Associate, FDA, Apoptosis, University of Washington Department of Bioengineering, Conference, CEO, Autophagy, Safety, Clinical trial, Pharmaceutical industry, Alzheimer's disease, Patient

Today AriBio Co., Ltd. announced the completion of the end of phase 2 meeting (EOP2) with the United States Food and Drug Administration (FDA), Division of Neurology 1.

Key Points: 
  • Today AriBio Co., Ltd. announced the completion of the end of phase 2 meeting (EOP2) with the United States Food and Drug Administration (FDA), Division of Neurology 1.
  • AriBio is very appreciative of the time and attention the FDA provided in preparation for and during this EOP2 meeting, said James Rock, CEO of AriBio USA, INC.
  • Importantly, AriBio was able to discuss the Phase 3 program including the target Alzheimers population and thoughts on acceptable endpoints for the study.
  • At this juncture of development, AriBio will move forward with protocol development and wait for the meeting minutes from the FDA to ensure alignment with our clinical program.

Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 4, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, United Kingdom, D, RAF, COVID-19, Private Securities Litigation Reform Act, Union, NASDAQ, LLC, American Association for Cancer Research, Tenosynovial giant cell tumor, Company, Medicine, United States security assistance to the Palestinian National Authority, Public expenditure, Safety, RECIST, Research, Patient, Binimetinib, ASMR, Association, Clinical trial, RAS, FDA, Cancer, American Association, NF1, U.S. Securities and Exchange Commission, GIST, LinkedIn, TGCT, MEK, SEC, AACR, Goal, Feedback, Autophagy, ULK, Phosphorylation, Pharmaceutical industry, Fossil fuel, Twitter, Health

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended March 31, 2022, and provided a corporate update.

Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended March 31, 2022, and provided a corporate update.
  • Expects to present updated results from the ongoing Phase 1/2 study in TGCT patients in the second half of 2022.
  • Deciphera will host a conference call and webcast to discuss this announcement today, May 4, 2022 at 8:00 AM ET.
  • Deciphera, the Deciphera logo, QINLOCK, and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC.

Immunoprime Combats Autophagy, Resets the Body, Restores Balance

Retrieved on: 
Tuesday, April 26, 2022
Coeliac disease, Immunity, Proton Inspira, Type 1, Psoriasis, GMP, Nutrient, Blood, Arthritis, Colostrum, Immune system, Skin, Environment, Human, TGA, HACCP, Quality of life, Health, Hair, Autophagy, Malnutrition, Vaccine, Dietary supplement, Cinnamon, Hair loss, Kashrut

FORT LAUDERDALE, Fla., April 26, 2022 /PRNewswire/ -- The development team behind the innovative health and wellness brand, Inspira Nutritionals, knows how difficult it can be to preserve one's health over time. This is particularly true if an individual is operating with struggling gut health or a compromised immune system.

Key Points: 
  • This is particularly true if an individual is operating with struggling gut health or a compromised immune system.
  • There are many serious health concerns that can trace their roots back to the digestive and immune systems.
  • These autoimmune concerns impact all areas of the body, from external elements, such as hair and skin to internal essentials, like bones and blood.
  • This has been used to create the company's flagship product, Immunoprime, which addresses immunity and digestive concerns.

Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting

Retrieved on: 
Tuesday, April 12, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, GIST, MEK, COVID-19, Association, NASDAQ, Patient, LinkedIn, U.S. Securities and Exchange Commission, Colorectal cancer, Large-cell lung carcinoma, American Association, FDA, Huntsman Cancer Institute, Drug development, Feedback, Annual report, Private Securities Litigation Reform Act, RAF, Phosphorylation, Company, View, Melanoma, Pharmacokinetics, LLC, Chloroquine, United Kingdom, RAS, SEC, American Association for Cancer Research, ULK, Safety, KRAS, Cancer, Drug resistance, Neoplasm, Union, AACR, Autophagy, Pharmaceutical industry, Vaccine, Medical imaging, Dermatology, Twitter, NSCLC

of Dermatology, Senior Director for Preclinical Translation and Co-Leader of the Experimental Therapeutics Program in the Huntsman Cancer Institute.

Key Points: 
  • of Dermatology, Senior Director for Preclinical Translation and Co-Leader of the Experimental Therapeutics Program in the Huntsman Cancer Institute.
  • Results from the preclinical studies showed that KRASG12C inhibitors, sotorasib and adagrasib, activate ULK-mediated autophagy as an adaptive treatment resistance mechanism.
  • Results demonstrated that DCC-3116 in combination with sotorasib and with adagrasib translated to deeper and longer tumor regressions in vivo.
  • Deciphera, the Deciphera logo, QINLOCK, and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC.